JP2014501780A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014501780A5 JP2014501780A5 JP2013548455A JP2013548455A JP2014501780A5 JP 2014501780 A5 JP2014501780 A5 JP 2014501780A5 JP 2013548455 A JP2013548455 A JP 2013548455A JP 2013548455 A JP2013548455 A JP 2013548455A JP 2014501780 A5 JP2014501780 A5 JP 2014501780A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- dosage form
- api
- solid dosage
- ethoxybenzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007909 solid dosage form Substances 0.000 claims 10
- 239000008186 active pharmaceutical agent Substances 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 239000008187 granular material Substances 0.000 claims 5
- 239000003472 antidiabetic agent Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- -1 4-chloro-3- (4-ethoxybenzyl) phenyl Chemical group 0.000 claims 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 239000000883 anti-obesity agent Substances 0.000 claims 2
- 229940125708 antidiabetic agent Drugs 0.000 claims 2
- 239000002220 antihypertensive agent Substances 0.000 claims 2
- 229940030600 antihypertensive agent Drugs 0.000 claims 2
- 239000003524 antilipemic agent Substances 0.000 claims 2
- 229940125710 antiobesity agent Drugs 0.000 claims 2
- 239000002830 appetite depressant Substances 0.000 claims 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical group OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 claims 2
- QKDRXGFQVGOQKS-CRSSMBPESA-N (2s,3r,4r,5s,6r)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol Chemical group C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](SC)O2)O)=CC=C1Cl QKDRXGFQVGOQKS-CRSSMBPESA-N 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- DVJAMEIQRSHVKC-BDAKNGLRSA-N Dutogliptin Chemical compound OB(O)[C@@H]1CCCN1C(=O)CN[C@H]1CNCC1 DVJAMEIQRSHVKC-BDAKNGLRSA-N 0.000 claims 1
- 150000004283 biguanides Chemical group 0.000 claims 1
- 230000036996 cardiovascular health Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims 1
- 229950003693 dutogliptin Drugs 0.000 claims 1
- 230000010034 metabolic health Effects 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims 1
- 229960003243 phenformin Drugs 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 229960004034 sitagliptin Drugs 0.000 claims 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161430027P | 2011-01-05 | 2011-01-05 | |
| US61/430,027 | 2011-01-05 | ||
| PCT/US2012/020042 WO2012094293A1 (en) | 2011-01-05 | 2012-01-03 | Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017019445A Division JP6682460B2 (ja) | 2011-01-05 | 2017-02-06 | ナトリウム−グルコース共輸送体１及びナトリウム−グルコース共輸送体２の阻害剤を含む組成物、並びに該阻害剤を使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014501780A JP2014501780A (ja) | 2014-01-23 |
| JP2014501780A5 true JP2014501780A5 (enExample) | 2015-02-19 |
Family
ID=45507917
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013548455A Pending JP2014501780A (ja) | 2011-01-05 | 2012-01-03 | ナトリウム−グルコース共輸送体１及びナトリウム−グルコース共輸送体２の阻害剤を含む組成物、並びに該阻害剤を使用する方法 |
| JP2017019445A Active JP6682460B2 (ja) | 2011-01-05 | 2017-02-06 | ナトリウム−グルコース共輸送体１及びナトリウム−グルコース共輸送体２の阻害剤を含む組成物、並びに該阻害剤を使用する方法 |
| JP2018218925A Pending JP2019048866A (ja) | 2011-01-05 | 2018-11-22 | ナトリウム−グルコース共輸送体１及びナトリウム−グルコース共輸送体２の阻害剤を含む組成物、並びに該阻害剤を使用する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017019445A Active JP6682460B2 (ja) | 2011-01-05 | 2017-02-06 | ナトリウム−グルコース共輸送体１及びナトリウム−グルコース共輸送体２の阻害剤を含む組成物、並びに該阻害剤を使用する方法 |
| JP2018218925A Pending JP2019048866A (ja) | 2011-01-05 | 2018-11-22 | ナトリウム−グルコース共輸送体１及びナトリウム−グルコース共輸送体２の阻害剤を含む組成物、並びに該阻害剤を使用する方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US20120172320A1 (enExample) |
| EP (1) | EP2661256B1 (enExample) |
| JP (3) | JP2014501780A (enExample) |
| KR (1) | KR102024204B1 (enExample) |
| CN (1) | CN103458875A (enExample) |
| AR (1) | AR084781A1 (enExample) |
| AU (1) | AU2012204567B9 (enExample) |
| BR (1) | BR112013017314B1 (enExample) |
| CA (1) | CA2823736C (enExample) |
| DK (1) | DK2661256T3 (enExample) |
| ES (1) | ES2710341T3 (enExample) |
| HU (1) | HUE041364T2 (enExample) |
| IL (1) | IL295438B1 (enExample) |
| MX (1) | MX360554B (enExample) |
| PL (1) | PL2661256T3 (enExample) |
| PT (1) | PT2661256T (enExample) |
| RU (1) | RU2669921C2 (enExample) |
| SG (2) | SG191865A1 (enExample) |
| TR (1) | TR201901262T4 (enExample) |
| TW (1) | TWI631963B (enExample) |
| WO (1) | WO2012094293A1 (enExample) |
| ZA (1) | ZA201304694B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9200025B2 (en) * | 2012-11-20 | 2015-12-01 | Lexicon Pharmaceuticals, Inc. | Inhibitors of sodium glucose cotransporter 1 |
| JP6727419B2 (ja) * | 2016-05-25 | 2020-07-22 | クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド | ナトリウム−グルコース共輸送体阻害薬の新規な結晶形及びその製造方法並びに用途 |
| US11723929B2 (en) | 2017-06-13 | 2023-08-15 | The Regents Of The University Of California | Methods of improving cell-based therapy |
| CN107540685B (zh) * | 2017-09-04 | 2020-05-05 | 杭州科巢生物科技有限公司 | 一种Sotagliflozin的制备方法及其中间体 |
| EP3456320A1 (de) * | 2017-09-15 | 2019-03-20 | Stada Arzneimittel Ag | Dpp-4-inhibitor-mono-zusammensetzung |
| JP6917527B2 (ja) * | 2018-01-05 | 2021-08-11 | シャンドン ダンホン ファーマスーティカル カンパニー リミテッドＳｈａｎｄｏｎｇ Ｄａｎｈｏｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | Ｓｇｌｔ阻害剤及びその応用 |
| CN110117304A (zh) * | 2018-04-23 | 2019-08-13 | 中国科学院成都生物研究所 | 一种钠-葡萄糖协同转运蛋白1和2抑制剂的药物用途 |
| CN110818722B (zh) * | 2018-08-14 | 2022-12-02 | 苏州鹏旭医药科技有限公司 | 三种化合物及其制备方法和在合成索格列净中的用途 |
| EP3957634A4 (en) | 2019-07-05 | 2022-08-31 | Shangdong Danhong Pharmaceutical Co., Ltd. | SGLT INHIBITOR IN CRYSTAL FORM AND ITS USE |
| US12378277B2 (en) | 2019-07-26 | 2025-08-05 | Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. | SGLTS/DPP4 inhibitor and application thereof |
| US12421269B2 (en) * | 2019-07-26 | 2025-09-23 | Cgenetech (Suzhou, China) Co., Ltd. | SGLT2/DPP4 inhibitor and application thereof |
| EP3771480A1 (en) | 2019-08-01 | 2021-02-03 | Lexicon Pharmaceuticals, Inc. | Continuous process for preparing the crystalline form ii of sotagliflozin |
| CA3156136A1 (en) * | 2019-11-07 | 2021-05-14 | Michael Hadd | Sodium-glucose linked transporter inhibitors for the management of chronic kidney disease, hypertension, and heart failure in companion animals |
| WO2022144465A1 (en) | 2021-01-04 | 2022-07-07 | Charité-Universitätsmedizin Berlin | Sotagliflozin for improving left atrial function |
| US20220370485A1 (en) | 2021-01-14 | 2022-11-24 | Lexicon Pharmaceuticals, Inc. | Compounds and methods for treating or preventing cardiovascular diseases and conditions |
| US20250108032A1 (en) | 2023-09-28 | 2025-04-03 | Lexicon Pharmaceuticals, Inc. | Methods of treating type 1 diabetes and kidney disease |
| AU2024356182A1 (en) | 2023-10-06 | 2026-04-09 | Lexicon Pharmaceuticals, Inc. | Methods of reducing the risk of cardiovascular events in patients with left ventricular hypertrophy |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB284425A (en) | 1926-11-22 | 1928-02-02 | James Last | Improvements in and relating to sand or like moulds for making castings |
| US3674836A (en) | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
| US4027009A (en) | 1973-06-11 | 1977-05-31 | Merck & Co., Inc. | Compositions and methods for depressing blood serum cholesterol |
| JPS5612114B2 (enExample) | 1974-06-07 | 1981-03-18 | ||
| US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
| US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
| US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| US4499289A (en) | 1982-12-03 | 1985-02-12 | G. D. Searle & Co. | Octahydronapthalenes |
| CA1327360C (en) | 1983-11-14 | 1994-03-01 | William F. Hoffman | Oxo-analogs of mevinolin-like antihypercholesterolemic agents |
| US4613610A (en) | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
| US4686237A (en) | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
| US4647576A (en) | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
| ATE60571T1 (de) | 1984-12-04 | 1991-02-15 | Sandoz Ag | Inden-analoga von mevalonolakton und ihre derivate. |
| US4668794A (en) | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
| KR900001212B1 (ko) | 1985-10-25 | 1990-02-28 | 산도즈 파마슈티칼스 코오포레이숀 | 메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도 |
| FR2596393B1 (fr) | 1986-04-01 | 1988-06-03 | Sanofi Sa | Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant |
| US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| ES2009918A6 (es) | 1987-05-22 | 1989-10-16 | Squibb & Sons Inc | Procedimiento para preparar inhibidores de hmg-coa-reductasa que contienen fosforo. |
| US4759923A (en) | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
| JP2569746B2 (ja) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
| US4924024A (en) | 1988-01-11 | 1990-05-08 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors, new intermediates and method |
| US4871721A (en) | 1988-01-11 | 1989-10-03 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors |
| NO177005C (no) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
| US5506219A (en) | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
| US5753675A (en) | 1989-03-03 | 1998-05-19 | Novartis Pharmaceuticals Corporation | Quinoline analogs of mevalonolactone and derivatives thereof |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| US5470845A (en) | 1992-10-28 | 1995-11-28 | Bristol-Myers Squibb Company | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia |
| US5594016A (en) | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
| JP3254219B2 (ja) | 1993-01-19 | 2002-02-04 | ワーナー−ランバート・コンパニー | 安定な経口用のｃｉ−９８１製剤およびその製法 |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
| US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
| US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
| US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
| AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US6236946B1 (en) | 1995-12-13 | 2001-05-22 | Thomas S. Scanlan | Nuclear receptor ligands and ligand binding domains |
| US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| US5962440A (en) | 1996-05-09 | 1999-10-05 | Bristol-Myers Squibb Company | Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method |
| US5885983A (en) | 1996-05-10 | 1999-03-23 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
| EP2583675A1 (en) | 1998-02-02 | 2013-04-24 | Trustees Of Tufts College | Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism |
| JP2002506075A (ja) | 1998-03-09 | 2002-02-26 | フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ | セリンペプチダーゼ調節剤 |
| DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
| HUP0104634A3 (en) | 1998-07-06 | 2002-11-28 | Bristol Myers Squibb Co | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| CO5200844A1 (es) * | 1999-09-17 | 2002-09-27 | Novartis Ag | Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes |
| TWI302149B (en) | 1999-09-22 | 2008-10-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
| US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| US6555519B2 (en) | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
| KR20040054729A (ko) | 2001-10-18 | 2004-06-25 | 브리스톨-마이어스 스큅 컴퍼니 | 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도 |
| UA80991C2 (en) * | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
| US7393836B2 (en) * | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
| TWI499414B (zh) * | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| US7846945B2 (en) | 2007-03-08 | 2010-12-07 | Lexicon Pharmaceuticals, Inc. | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use |
| TW200904405A (en) * | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Pharmaceutical formulations containing an SGLT2 inhibitor |
| CL2008003653A1 (es) * | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| TWI472521B (zh) * | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法 |
| KR100968825B1 (ko) * | 2008-07-18 | 2010-07-08 | 현대자동차주식회사 | 차량용 트위터 스피커 |
| DK2396005T3 (da) * | 2009-02-13 | 2026-02-09 | Boehringer Ingelheim Int | Sglt2 hæmmer til at forbedre glykæmisk kontrol |
| JP5685550B2 (ja) * | 2009-02-13 | 2015-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用 |
| JP2012528170A (ja) * | 2009-05-27 | 2012-11-12 | ブリストル−マイヤーズ スクイブ カンパニー | 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法 |
| US20110077212A1 (en) * | 2009-09-25 | 2011-03-31 | Theracos, Inc. | Therapeutic uses of sglt2 inhibitors |
| ES2689107T3 (es) * | 2009-11-13 | 2018-11-08 | Astrazeneca Ab | Formulaciones de tabletas bicapa |
| TWI562775B (en) * | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
-
2012
- 2012-01-02 TW TW101100085A patent/TWI631963B/zh active
- 2012-01-03 IL IL295438A patent/IL295438B1/en unknown
- 2012-01-03 EP EP12700583.3A patent/EP2661256B1/en active Active
- 2012-01-03 SG SG2013052048A patent/SG191865A1/en unknown
- 2012-01-03 RU RU2013136384A patent/RU2669921C2/ru active
- 2012-01-03 PL PL12700583T patent/PL2661256T3/pl unknown
- 2012-01-03 KR KR1020137020505A patent/KR102024204B1/ko active Active
- 2012-01-03 PT PT12700583T patent/PT2661256T/pt unknown
- 2012-01-03 CN CN2012800047717A patent/CN103458875A/zh active Pending
- 2012-01-03 HU HUE12700583A patent/HUE041364T2/hu unknown
- 2012-01-03 DK DK12700583.3T patent/DK2661256T3/en active
- 2012-01-03 BR BR112013017314-9A patent/BR112013017314B1/pt active IP Right Grant
- 2012-01-03 TR TR2019/01262T patent/TR201901262T4/tr unknown
- 2012-01-03 CA CA2823736A patent/CA2823736C/en active Active
- 2012-01-03 ES ES12700583T patent/ES2710341T3/es active Active
- 2012-01-03 JP JP2013548455A patent/JP2014501780A/ja active Pending
- 2012-01-03 WO PCT/US2012/020042 patent/WO2012094293A1/en not_active Ceased
- 2012-01-03 AU AU2012204567A patent/AU2012204567B9/en active Active
- 2012-01-03 MX MX2013007826A patent/MX360554B/es active IP Right Grant
- 2012-01-03 US US13/342,421 patent/US20120172320A1/en not_active Abandoned
- 2012-01-03 SG SG10201602670QA patent/SG10201602670QA/en unknown
- 2012-01-04 AR ARP120100021 patent/AR084781A1/es unknown
-
2013
- 2013-06-24 ZA ZA2013/04694A patent/ZA201304694B/en unknown
-
2014
- 2014-05-30 US US14/291,804 patent/US20150111840A1/en not_active Abandoned
-
2015
- 2015-11-19 US US14/945,977 patent/US20160296547A1/en not_active Abandoned
-
2017
- 2017-02-06 JP JP2017019445A patent/JP6682460B2/ja active Active
-
2018
- 2018-04-30 US US15/966,238 patent/US20180311266A1/en not_active Abandoned
- 2018-11-22 JP JP2018218925A patent/JP2019048866A/ja active Pending
-
2020
- 2020-02-17 US US16/792,803 patent/US20210038626A1/en not_active Abandoned
-
2023
- 2023-01-10 US US18/095,058 patent/US20230218650A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014501780A5 (enExample) | ||
| RU2013136384A (ru) | Композиция, содержащая ингибиторы котранспортеров натрия-глюкозы 1 и 2, и способы их применения | |
| HRP20170093T1 (hr) | Kombinacije koje sadrže derivate 6-benzilfenil-2-sumporterahidropiran-3,4,5-triola kao inhibitore kotransportera natrijeve-glukoze 1 i 2 za uporabu kod pacijenata s dijabetesom | |
| JP2015120736A5 (enExample) | ||
| CN105873571B (zh) | 包含依泽替米贝和瑞舒伐他汀的口服复合制剂 | |
| NZ590184A (en) | Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use | |
| JP2013509429A5 (enExample) | ||
| JP2010513478A5 (enExample) | ||
| JP2016041701A5 (enExample) | ||
| JP2009500443A5 (enExample) | ||
| JP2012031131A5 (enExample) | ||
| RU2017109139A (ru) | Таблетки, содержащие большую дозу рукапариба | |
| IL274943B1 (en) | Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases | |
| JP2010522244A5 (enExample) | ||
| JP2006298933A5 (enExample) | ||
| JP2010248252A5 (enExample) | ||
| WO2011079239A3 (en) | Combination tablet with chewable outer layer | |
| JP2012520883A5 (enExample) | ||
| WO2009010416A3 (en) | Inhibitors of 11b-hydroxysteroid dehydrogenase | |
| WO2011005811A8 (en) | Combination therapy for the treatment of diabetes | |
| WO2016060517A3 (ko) | 신규한 3-(4- (벤질옥시)페닐)핵스- 4-이노익 산 유도체 및 다른 유효 성분을 포함하는 대사성 질환의 예방 또는 치료용 복합제제 | |
| JP2012193216A5 (enExample) | ||
| JP2012512164A5 (enExample) | ||
| JP2015511635A5 (enExample) | ||
| WO2012148252A3 (es) | Cocristales ionicos con base en metformina |